Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
AstraZeneca
Baxter
Cantor Fitzgerald
Julphar
McKinsey
Covington
Queensland Health

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,928,115

« Back to Dashboard

Which drugs does patent 7,928,115 protect, and when does it expire?

Patent 7,928,115 protects XIFAXAN and is included in one NDA.

This patent has thirty-two patent family members in eleven countries.
Summary for Patent: 7,928,115
Title:Methods of treating travelers diarrhea and hepatic encephalopathy
Abstract: Treatment of traveler's diarrhea in subjects having hepatic encephalopathy using rifaximin is disclosed.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chappel Hill, NC)
Assignee: Salix Pharmaceuticals, Ltd. (Morrisville, NC)
Application Number:12/957,831
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,928,115

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING TRAVELERS' DIARRHEA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,928,115

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,629,829 Methods of treating hepatic encephalopathy ➤ Try a Free Trial
8,946,252 Methods of treating traveler's diarrhea and hepatic encephalopathy ➤ Try a Free Trial
8,969,398 Methods of treating hepatic encephalopathy ➤ Try a Free Trial
8,642,573 Methods of treating hepatic encephalopathy ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,928,115

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009298389 ➤ Try a Free Trial
Australia 2010260089 ➤ Try a Free Trial
Australia 2010271070 ➤ Try a Free Trial
Canada 2739436 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Johnson and Johnson
Chinese Patent Office
Healthtrust
Merck
Cantor Fitzgerald
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.